When patients present with symptoms related to functional gastrointestinal (GI) disorders or Disorders of the Gut-Brain Interaction (DGBI) like Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and Carbohydrate Malabsorption, the recommended method of diagnosis is clinical breath testing.
Each breath test – overseen by providers at healthcare facilities or taken by patients in the comfort of their own home – presents an opportunity for a GI practice to capture clinically essential patient data and generate revenue for the service it provides its patients. Yet, the differences in upfront costs and revenue potential between point-of-care breath testing and at-home breath testing are significant.
This guide provides an in-depth look at these two breath test processes – point-of-care and at-home – including a pro-forma analysis of potential costs and revenue associated with both.

Download our Breath Testing Pro Forma Comparison:

  • This field is for validation purposes and should be left unchanged.